보툴리눔 톡신
Product profile of THE TOXIN™
Product
Specification
THE TOXIN™ Future R&D
Indication Glabella line
Strain ATCC3502
(NCTC 13319)
Type B
Type E
PFS
Origin of Strain Officially acquired from EU Officially acquired from EU
Type Type A Type B
Type E
Model 50U, 100U, 200U on developing
Duration 3~4M for glabella line
Indication Facial wrinkle
Masseter muscle reduction
Spasticity
Spasm, Pain
Hair loss, Scar
On set time 2-3 days 1 day
Conversion ration
with Botox, Allergan
1:1 on developing
Purity 98.9% ≤ on developing
Total protein 2.4 ng / 100 U on developing
Feature of THE TOXIN™
HPLC
  • Analysis of DS assay
  • Contents of neurotoxin
Non clinical trial result of THE TOXIN™
1. Electromyogram Flow : Faster and higher change in electromyogram reduction
Efficacy The Toxin has fast on set of time and long duration.
2. Muscle Weight Change(4wks after Injection) : More muscle weight change
Safety Safety is proven in terms of muscle of mouse weight change.
Reference : Tested by Chungang university college of Medicine
Registration schedule of THE TOXIN™